Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 13/20 | 0.40 |
| ▸ | GPR142 | Q7Z601 | 1/20 | 0.34 |
| ▸ | IGF1R | P08069 | 1/20 | 0.33 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.32 |
| ▸ | ALKBH3 | Q96Q83 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL856691 | 0.91 | PIK3CA (0.34) | PIK3CAGPR142CREBBP | |
| SCHEMBL3760455 | 0.88 | PIK3CA (0.41) | PIK3CAGPR142CREBBP | |
| SCHEMBL861032 | 0.87 | PIK3CA (0.47) | PIK3CAGPR142IGF1RCREBBPALKBH3 | |
| SCHEMBL857055 | 0.86 | GRIA1 (0.43) | PIK3CAIGF1RALKBH3 | |
| SCHEMBL13056674 | 0.85 | MAPK1 (0.41) | PIK3CAGPR142LMNA | |
| SCHEMBL856540 | 0.83 | PIK3CA (0.39) | PIK3CAGPR142IGF1RALKBH3 | |
| SCHEMBL856829 | 0.82 | GPR142 (0.41) | PIK3CAGPR142CREBBP | |
| SCHEMBL861665 | 0.81 | PIK3CA (0.47) | PIK3CAIGF1RCREBBP | |
| SCHEMBL858375 | 0.81 | PIK3CA (0.46) | PIK3CAIGF1RCREBBPALKBH3 | |
| SCHEMBL855715 | 0.81 | PIK3CA (0.46) | PIK3CAIGF1RCREBBPCHEK2ALKBH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140080810-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | EXELIXIS, INC. (US) | 2014-03-20 | — | — | US | disclosed |
| EP-2432779-A1 | BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES | Exelixis, Inc. (US) | 2012-03-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140080810-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | MTOR, RICTOR, PIK3CA | PIK3CA 3/4885GPR142 2004/4885IGF1R 794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.